Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye
The epidemiology, risk factors, and the effect of anti-VEGF treatment on neovascular age-related macular degeneration (nAMD) have primarily been studied in the first eye developing the disease. The understanding of pathophysiology and planning of follow-up examinations can be improved by knowledge of incidence and risk factors for development of the disease in the fellow eye.
In a prospective observational cohort study, epidemiological and clinical risk factors for the development of nAMD in the fellow eye among 2516 patients consecutively diagnosed with the disease from a population of 0.9 million citizens during a period of more than 10 years were studied.
nAMD had been diagnosed in the fellow eye of 541 (21.5%) of the patients. The incidence of fellow-eye involvement increased from approximately 5% in patients initially presenting with bilateral disease to approximately 28% more than 6 years after the diagnosis in the first eye. Visual acuity (VA) was higher and central retinal thickness (CRT) was lower in fellow eyes with nAMD diagnosed later than the first eye. Male gender, increasing leakage area, and peripapillary location of the subretinal neovascular membrane in the first eye reduced the risk of developing disease in the fellow eye.
The planning of follow-up examinations of patients diagnosed with nAMD in one eye should consider that the risk of fellow-eye involvement is higher within the first 6 years, in women, and when the leakage area in the first eye is small and not located peripapillary.
KeywordsNeovascular age-related macular degeneration Anti-VEGF treatment Fellow eye Risk factors
The skillful assistance of biostatistician Anders Michelsen is gratefully acknowledged.
Compliance with ethical standards
The study was approved by The Central Denmark Region Committees for Health Research Ethics.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent was not required, but informed consent for quality assessment of treatment was obtained anyway. No identifying information about individual participants is provided in the manuscript.
- 6.Maguire MG, Daniel E, Shah AR et al (2013) Comparison of age-related macular degeneration treatments trials (CATT research group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120(10):2035–2041CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Bek T, Klug SE (2018) Age, gender and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration. Int Ophthalmol 12:473–479Google Scholar
- 12.Solomon SD, Jefferys JL, Hawkins BS, Bressler NM, Bressler SB, Submacular Surgery Trials Research Group (2009) Risk factors for second eye progression to advanced age-related macular degeneration: SST report no. 21. Submacular Surgery Trials Research Group. Retina 29(8):1080–1090CrossRefPubMedGoogle Scholar